Grifols, S.A. (GRFS) Cut to Neutral at Goldman Sachs Group, Inc. (The)
Grifols, S.A. (NASDAQ:GRFS) was downgraded by equities researchers at Goldman Sachs Group, Inc. (The) from a “buy” rating to a “neutral” rating in a research note issued on Friday.
A number of other brokerages also recently weighed in on GRFS. Zacks Investment Research downgraded Grifols, from a “buy” rating to a “hold” rating in a research report on Friday, May 5th. BidaskClub upgraded Grifols, from a “hold” rating to a “buy” rating in a research note on Friday, June 23rd. Bank of America Corporation initiated coverage on Grifols, in a research note on Thursday, April 6th. They issued a “buy” rating for the company. J P Morgan Chase & Co upgraded Grifols, from a “neutral” rating to an “overweight” rating in a research note on Thursday, March 30th. Finally, HSBC Holdings plc cut Grifols, from a “hold” rating to a “reduce” rating in a research note on Friday, April 7th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $19.00.
Shares of Grifols, (GRFS) traded down 0.24% during mid-day trading on Friday, hitting $21.10. 81,124 shares of the stock were exchanged. The firm has a market cap of $28.27 billion, a P/E ratio of 45.97 and a beta of 1.03. Grifols, has a 12 month low of $14.27 and a 12 month high of $22.83. The stock’s 50 day moving average is $21.42 and its 200 day moving average is $18.78.
The firm also recently disclosed a semiannual dividend, which was paid on Thursday, June 8th. Shareholders of record on Thursday, June 1st were issued a $0.122 dividend. This represents a yield of 1.54%. The ex-dividend date was Tuesday, May 30th. Grifols,’s payout ratio is currently 30.77%.
TRADEMARK VIOLATION WARNING: This piece was published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://www.americanbankingnews.com/2017/06/30/grifols-s-a-grfs-cut-to-neutral-at-goldman-sachs-group-inc-the.html.
Hedge funds have recently modified their holdings of the company. AKO Capital LLP bought a new position in Grifols, during the first quarter worth $36,979,000. FMR LLC raised its position in Grifols, by 52.6% in the first quarter. FMR LLC now owns 6,352,581 shares of the biotechnology company’s stock worth $119,905,000 after buying an additional 2,189,431 shares during the period. JPMorgan Chase & Co. raised its position in Grifols, by 25.1% in the first quarter. JPMorgan Chase & Co. now owns 1,926,442 shares of the biotechnology company’s stock worth $36,362,000 after buying an additional 385,998 shares during the period. Karp Capital Management Corp bought a new position in Grifols, during the first quarter worth $4,916,000. Finally, Gladstone Capital Management LLP raised its position in Grifols, by 34.0% in the first quarter. Gladstone Capital Management LLP now owns 1,020,162 shares of the biotechnology company’s stock worth $21,842,000 after buying an additional 258,896 shares during the period. 22.12% of the stock is currently owned by hedge funds and other institutional investors.
Receive News & Ratings for Grifols S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grifols S.A. and related companies with MarketBeat.com's FREE daily email newsletter.